Haemovigilance in Polytransfused patients reported with adverse transfusion reactions in Colombia

María Isabel Bermúdez-Forero; Michel Andres Garcia Otalora

Resumen

Introducción: Desde el 1 de enero de 2018, el Instituto Nacional de Salud de Colombia ha recolectado toda la información relacionada con transfusión sanguínea a nivel nacional en el Sistema Nacional de Hemovigilancia (SIHEVI-INS). A finales de 2022 se transfundieron 6.636.499 componentes sanguíneos a 1.794.315 pacientes, determinando un índice de 3,7 componentes sanguíneos por paciente (Figura 1). Aún no existe un consenso internacional respecto a la definición de pacientes politransfundidos. En 2019, Colombia estableció que todo paciente que haya recibido seis o más componentes sanguíneos debe ser clasificado como tal. Se desconoce cuántos colombianos han recibido seis o más componentes sanguíneos y han presentado reacciones adversas a la transfusión (RAM). Estos datos son necesarios para caracterizar la población, evaluar las posibles infecciones transmitidas por transfusión y la propagación de las mismas a los contactos cercanos. Asimismo, estos datos son necesarios para reducir la probabilidad de aloinmunización, refractariedad, incompatibilidad, hematopoyesis defectuosa por sobrecarga de hierro y alteraciones endocrinas. Este trabajo tiene como objetivo presentar la caracterización de la población notificada con RTA que cumple con los criterios definidos de politransfundida en Colombia. Métodos: Los pacientes fueron identificados de acuerdo con su número único de identificación en el SIHEVI-INS. Se incluyeron aquellos pacientes con RTA y transfusión de seis o más componentes sanguíneos en uno o más momentos durante el periodo de estudio. La Base de Datos Única de Afiliados al Régimen General de la Seguridad Social en Salud determinó su situación hasta abril de 2023 (vivos o fallecidos). Resultados: De las personas registradas en RTA entre 2018-2022, se identificaron 592 que recibieron en promedio 8,2 componentes sanguíneos. El 54% de los pacientes vivos eran mujeres (OR: 0,61; IC 95%: 0,43-0,86) (Figura 2). El 59,6% de los pacientes politransfundidos eran O positivos, seguidos de A positivos (26,2%), B positivos (7,0%) y O negativos (3,6%). De los pacientes fallecidos, el 53% eran hombres (OR: 1,54; IC 95%: 1,08-2,21). Del total de reacciones adversas, el 77,3% correspondieron a acontecimientos alérgicos, el 7,9% a acontecimientos febriles no hemolíticos y el 4,1% a sobrecarga circulatoria asociada a la transfusión. Se estimó la frecuencia de 1 politransfundido por cada 3.030 pacientes notificados. Por lo tanto, si anualmente se transfunden unos 358.863 pacientes, se podría deducir que 118 serían potencialmente politransfundidos. Discusión: Ser politransfundido y presentar RTA es un predictor de muerte cinco años después de la notificación.

Título traducido de la contribución	Hemovigilancia en pacientes multitransfundidos reportados con reacciones adversas a la transfusión en Colombia
Idioma original	Inglés estadounidense
Páginas	26-27
Número de páginas	2
Estado	Publicada - jul 1 2023
Evento	The 33rd Regional Congress of the ISBT Gothenburg, Sweeden.: The 33rd Regional Congress of the ISBT - Swedish Congress and Convention Center, Gotenburgo, Suecia Duración: jun 18 2023 → jun 18 2023 Número de conferencia: 1 https://7d330759.flowpaper.com/TransfusionTodayJuli2023/#page=12

Exposición

Exposición	The 33rd Regional Congress of the ISBT Gothenburg, Sweeden.
Título abreviado	33rd Regional Congress ISBT
País/Territorio	Suecia
Ciudad	Gotenburgo
Período	6/18/23 → 6/18/23
Dirección de internet	https://7d330759.flowpaper.com/TransfusionTodayJuli2023/#page=12

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Áreas temáticas de ASJC Scopus

Hematología

Acceder al documento

https://7d330759.flowpaper.com/TransfusionTodayJuli2023/#page=26Licencia: Sin especificar

Citar esto

@conference{56edaa93c232411998e35ba0ec3c9e0e,

title = "Haemovigilance in Polytransfused patients reported with adverse transfusion reactions in Colombia",

abstract = "Introduction: Since January 1, 2018, the Colombian National Institute of Health has collected all the information related to blood transfusion nationwide in the National Haemovigilance System (SIHEVI-INS). By the end of 2022, 6,636,499 blood components were transfused to 1,794,315 patients, determining an index of 3.7 blood components per patient (Figure 1). There has yet to be an international consensus regarding the definition of polytransfused patients. In 2019, Colombia established that any patient who received six or more blood components should be classified as such. How many Colombians have received six or more blood components and presented adverse transfusion reactions (ATR) is unknown. These data are required to characterize the population, assess potential transfusion-transmitted infections and the spread of them to close contacts. Likewise, these data are required to reduce the probability of alloimmunization, refractoriness, incompatibility, defective hematopoiesis due to iron overload, and endocrine alterations. This work aims to present the characterization of the population notified with ATR that meets the defined criteria of polytransfused in Colombia. Methods: Patients were identified according to their unique identification number in SIHEVI-INS. Those patients with ATR and transfusion of six or more blood components at one or more moments during the study period were included. The Single Database of Affiliates of the General System of Social Security in Health determined their status until April 2023 (alive or deceased). Results: Of the people registered with ATR between 2018-2022, 592 were identified who received an average of 8.2 blood components. 54\% of the living patients were women (OR: 0.61; 95\% CI: 0.43-0.86) (Figure 2). 59.6\% of polytransfused patients were O positive, followed by A positive (26.2\%), B positive (7.0\%), and O negative (3.6\%). Of the deceased patients, 53\% were men (OR: 1.54, 95\% CI: 1.08-2.21). Of the total adverse reactions, 77.3\% corresponded to allergic events, 7.9\% to non-hemolytic febrile events, and 4.1\% to Transfusion-associated circulatory overload. The frequency of 1 polytransfused was estimated for every 3,030 patients notified. Therefore, if there are around 358,863 patients transfused annually, it could be inferred that 118 would be potentially polytransfused. Discussion: Being polytransfused and presenting ATR is a predictor of death five years after notification.",

author = "Berm{\'u}dez-Forero, \{Mar{\'i}a Isabel\} and \{Garcia Otalora\}, \{Michel Andres\}",

year = "2023",

month = jul,

day = "1",

language = "English (US)",

pages = "26--27",

note = "The 33rd Regional Congress of the ISBT Gothenburg, Sweeden. ; Conference date: 18-06-2023 Through 18-06-2023",

url = "https://7d330759.flowpaper.com/TransfusionTodayJuli2023/\#page=12",

}

TY - CONF

T1 - Haemovigilance in Polytransfused patients reported with adverse transfusion reactions in Colombia

AU - Bermúdez-Forero, María Isabel

AU - Garcia Otalora, Michel Andres

N1 - Conference code: 1

PY - 2023/7/1

Y1 - 2023/7/1

N2 - Introduction: Since January 1, 2018, the Colombian National Institute of Health has collected all the information related to blood transfusion nationwide in the National Haemovigilance System (SIHEVI-INS). By the end of 2022, 6,636,499 blood components were transfused to 1,794,315 patients, determining an index of 3.7 blood components per patient (Figure 1). There has yet to be an international consensus regarding the definition of polytransfused patients. In 2019, Colombia established that any patient who received six or more blood components should be classified as such. How many Colombians have received six or more blood components and presented adverse transfusion reactions (ATR) is unknown. These data are required to characterize the population, assess potential transfusion-transmitted infections and the spread of them to close contacts. Likewise, these data are required to reduce the probability of alloimmunization, refractoriness, incompatibility, defective hematopoiesis due to iron overload, and endocrine alterations. This work aims to present the characterization of the population notified with ATR that meets the defined criteria of polytransfused in Colombia. Methods: Patients were identified according to their unique identification number in SIHEVI-INS. Those patients with ATR and transfusion of six or more blood components at one or more moments during the study period were included. The Single Database of Affiliates of the General System of Social Security in Health determined their status until April 2023 (alive or deceased). Results: Of the people registered with ATR between 2018-2022, 592 were identified who received an average of 8.2 blood components. 54% of the living patients were women (OR: 0.61; 95% CI: 0.43-0.86) (Figure 2). 59.6% of polytransfused patients were O positive, followed by A positive (26.2%), B positive (7.0%), and O negative (3.6%). Of the deceased patients, 53% were men (OR: 1.54, 95% CI: 1.08-2.21). Of the total adverse reactions, 77.3% corresponded to allergic events, 7.9% to non-hemolytic febrile events, and 4.1% to Transfusion-associated circulatory overload. The frequency of 1 polytransfused was estimated for every 3,030 patients notified. Therefore, if there are around 358,863 patients transfused annually, it could be inferred that 118 would be potentially polytransfused. Discussion: Being polytransfused and presenting ATR is a predictor of death five years after notification.

AB - Introduction: Since January 1, 2018, the Colombian National Institute of Health has collected all the information related to blood transfusion nationwide in the National Haemovigilance System (SIHEVI-INS). By the end of 2022, 6,636,499 blood components were transfused to 1,794,315 patients, determining an index of 3.7 blood components per patient (Figure 1). There has yet to be an international consensus regarding the definition of polytransfused patients. In 2019, Colombia established that any patient who received six or more blood components should be classified as such. How many Colombians have received six or more blood components and presented adverse transfusion reactions (ATR) is unknown. These data are required to characterize the population, assess potential transfusion-transmitted infections and the spread of them to close contacts. Likewise, these data are required to reduce the probability of alloimmunization, refractoriness, incompatibility, defective hematopoiesis due to iron overload, and endocrine alterations. This work aims to present the characterization of the population notified with ATR that meets the defined criteria of polytransfused in Colombia. Methods: Patients were identified according to their unique identification number in SIHEVI-INS. Those patients with ATR and transfusion of six or more blood components at one or more moments during the study period were included. The Single Database of Affiliates of the General System of Social Security in Health determined their status until April 2023 (alive or deceased). Results: Of the people registered with ATR between 2018-2022, 592 were identified who received an average of 8.2 blood components. 54% of the living patients were women (OR: 0.61; 95% CI: 0.43-0.86) (Figure 2). 59.6% of polytransfused patients were O positive, followed by A positive (26.2%), B positive (7.0%), and O negative (3.6%). Of the deceased patients, 53% were men (OR: 1.54, 95% CI: 1.08-2.21). Of the total adverse reactions, 77.3% corresponded to allergic events, 7.9% to non-hemolytic febrile events, and 4.1% to Transfusion-associated circulatory overload. The frequency of 1 polytransfused was estimated for every 3,030 patients notified. Therefore, if there are around 358,863 patients transfused annually, it could be inferred that 118 would be potentially polytransfused. Discussion: Being polytransfused and presenting ATR is a predictor of death five years after notification.

M3 - Abstract

SP - 26

EP - 27

T2 - The 33rd Regional Congress of the ISBT Gothenburg, Sweeden.

Y2 - 18 June 2023 through 18 June 2023

ER -